Page 66 - 77_04

NANOTERAPIAS
ONCOLÓGICAS……

29.
Duncan,
R.
(2006).
Polymer
conjugates
as
anticancer
nanomedicines.
Nature
Reviews
Cancer,

6(9),

688-­-701.

30.
Vicent,
M.J.,
&
al.
(2006).
Polymer
conjugates:
nanosized
medicines
for
treating
cancer.
Trends

in
Biotechnology,
24(1),

39-­-47.

31.
Graham,
M.L.
(2003).
Pegaspargase:
a
review
of
clinical
studies.
Advanced
Drug
Delivery

Reviews,
55(10),

1293-­-1302.

32.
Canal,
F.,
&
al.
Polymer–drug
conjugates
as
nano-­-sized
medicines.
Current
Opinion
in

Biotechnology,
22,
894-­-900.

33.
Campone,
M.,
&
al.
(2007).P
hase
I
&
pharmacokinetic
trial
of
AP5346,
a
DACH–platinum–
polymer
conjugate,
administered
weekly
for
three
out
of
every
4
weeks
to
advanced
solid

tumor
patients.
Cancer
Chemotherapy
&
Pharmacology,

60(4),

523-­-533.

34.
Nowotnik,
D.
&
al.
(2009).
ProLindac™
(AP5346):
A
review
of
the
development
of
an
HPMA

DACH
platinum
Polymer
Therapeutic.
Advanced
Drug
Delivery
Reviews,
61(13),

1214-­-1219.

35.
Li,
C.,
&
al.
(2008).
Polymer-­-drug
conjugates:
Recent
development
in
clinical
oncology.

Advanced
Drug
Delivery
Reviews,
60(8),

886-­-898.

36.
Pasut,
G.,
&
al.
(2009).
PEG
conjugates
in
clinical
development
or
use
as
anticancer
agents:
An

overview.
,
Advanced
Drug
Delivery
Reviews61(13),

1177-­-1188.

37.
Schluep,
T.,
&
al.
(2006).
Preclinical
Efficacy
of
the
Camptothecin-­-Polymer
Conjugate
IT-­-101
in

Multiple
Cancer
Models.
Clinical
Cancer
Research,
12(5),

1606-­-1614.

38.
Blanco,
E.,
&
al.,
(2011).
Nanomedicine
in
cancer
therapy:
Innovative
trends
&
prospects.

Cancer
Science,

102(7),

1247-­-1252.

39.
Oerlemans,
C.,
&
al.,
(2010).
Polymeric
Micelles
in
Anticancer
Therapy:
Targeting,
Imaging
&

Triggered
Release.
Pharmaceutical
Research,
27(12),

2569-­-2589.

40.
NK105
Paclitaxel
Micelle.
(2011).

(cited
2011
17-­-10-­-2011);
Available
from:

http://www.nanocarrier.co.jp/en/research/pipeline/01.html.

41.
Kato,
K.,
&
al.
Phase
II
study
of
NK105,
a
paclitaxel-­-incorporating
micellar
nanoparticle,
for

previously
treated
advanced
or
recurrent
gastric
cancer.
Investigational
New
Drugs,

1-­-7.

42.
Yasuhiro,
M.
(2011).
Preclinical
&
clinical
studies
of
NK012,
an
SN-­-38-­-incorporating
polymeric

micelles,
which
is
designed
based
on
EPR
effect.
Advanced
Drug
Delivery
Reviews,
63(3),

184-­-
192.

43.
Kataoka,
K.,
&
al.
(2006).
Polymeric
micelle
containing
cisplatin
enclosed
therein
&
use
thereof,

Toudai
TLO,
Ltd.:
USA.

44.
Uchino,
H.,
&
al.
(2005).
Cisplatin-­-incorporating
polymeric
micelles
(NC-­-6004)
can
reduce

nephrotoxicity
&
neurotoxicity
of
cisplatin
in
rats.
British
Journal
of
Cancer,
93(6),

678-­-687.

45.
Lee,
S.-­-W.,
&
al.
Development
of
docetaxel-­-loaded
intravenous
formulation,
Nanoxel-­-PM™
using

polymer-­-based
delivery
system.
Journal
of
Controlled
Release,
155,
262-­-271.

46.
Paszko,
E.,
&
al.
(2011).
Nanodrug
applications
in
photodynamic
therapy.
Photodiagnosis
&

Photodynamic
Therapy,
8(1),

14-­-29.

47.
Sharma,
R.,
&
al.
(2009).
Newer
nanoparticles
in
hyperthermia
treatment
&
thermometry.

Journal
of
Nanoparticle
Research,
11(3),

671-­-689.

48.
Rozanova,
N.,
&
al.
(2008).

Metal
&
Magnetic
Nanostructures
for
Cancer
Detection,
Imaging,
&

Therapy.
Journal
of
Biomedical
Nanotechnology,
4(4),

377-­-399.

49.
Prijic,
S.,
et
al.
(2011).
Magnetic
nanoparticles
as
targeted
delivery
systems
in
oncology.

Radiology
&
Oncology,

45(1),

1-­-16.

50.
Jordan,
A.,
&
al.
(1999).
Endocytosis
of
dextran
&
silan-­-coated
magnetite
nanoparticles
&
the

effect
of
intracellular
hyperthermia
on
human
mammary
carcinoma
cells
in
vitro.
Journal
of

Magnetism
&
Magnetic
Materials,
194(1-­-3),

185-­-196.

97